Program
CBL-514
A development code. Also written as “CBL-514 Injection”, “CBL-514 injection” and “40 mg CBL-514”.
Its studies are mostly in Cellulite · Lipedema, led by Caliway Biopharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Caliway Biopharmaceuticals | 165 open or running | phase 3since Aug 21, 2025 | Aug 19, 2020 | Apr 2027phase 2 · NCT07608770 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Aug 19, 2020.
- Dec 29, 2020Phase 1 study in Subcutaneous FatNCT04699669 · 40 enrolled · Australia
- Dec 29, 2020Phase 2 study in Subcutaneous FatNCT04698642 · 43 enrolled · Australia
- May 18, 2021Phase 2 study in Subcutaneous FatNCT04897412 · 75 enrolled · United States, Australia
- Dec 23, 2021Phase 2 study in Subcutaneous FatNCT05234736 · 10 enrolled · United States
- May 19, 2022Phase 2 study in Adiposis DolorosaNCT05387733 · 12 enrolled · United States
- Nov 21, 2022Phase 2 study in CelluliteNCT05632926 · 12 enrolled · United States
- Feb 10, 2023Phase 2 study in Subcutaneous FatNCT05736107 · 107 enrolled · United States
- Apr 19, 2023Phase 2 study in CelluliteNCT05836779 · 23 enrolled · United States
- Aug 10, 2023Phase 2 study in Subcutaneous FatNCT06005441 · 173 enrolled · United States
- Feb 26, 2024Phase 2 study in Adiposis DolorosaNCT06303570 · 19 enrolled · United States
- Aug 21, 2025Phase 3 study in Subcutaneous FatNCT07140939 · 320 planned · United States, Canada
- Apr 8, 2026Phase 3 study in Subcutaneous FatNCT07526974 · 320 planned · United States, Australia, Canada
- May 19, 20262 phase 2 studies in Subcutaneous FatNCT07608770, NCT07608757
- Jul 24, 2026Phase 3 study in Subcutaneous FatNCT07733947 · 300 planned · United States
Ahead
- Apr 2027Primary completion: phase 2 study in Subcutaneous FatNCT07608770
- Jul 2027Primary completion: phase 3 study in Subcutaneous FatNCT07140939
- Aug 2027Primary completion: phase 3 study in Subcutaneous FatNCT07526974
- Feb 2028Primary completion: phase 2 study in Subcutaneous FatNCT07608757
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07733947Subcutaneous Fat · United States | 3 | Not yet recruiting | Aug 2028 | 300 |
| NCT07608757Subcutaneous Fat · Australia | 2 | Not yet recruiting | Feb 2028 | 250 |
| NCT07608770Subcutaneous Fat · Australia | 2 | Recruiting | Apr 2027 | 250 |
| NCT07526974Subcutaneous Fat · United States, Australia, Canada | 3 | Not yet recruiting | Aug 2027 | 320 |
| NCT07140939Subcutaneous Fat · United States, Canada | 3 | Recruiting | Jul 2027 | 320 |
| NCT06303570Adiposis Dolorosa · United States | 2 | Completed | Mar 23, 2026 | 19 |
| NCT06005441Subcutaneous Fat · United States | 2 | Completed | Oct 18, 2024 | 173 |
| NCT05836779Cellulite · United States | 2 | Completed | Nov 29, 2023 | 23 |
| NCT05736107Subcutaneous Fat · United States | 2 | Completed | May 20, 2024 | 107 |
| NCT05632926Cellulite · United States | 2 | Completed | May 3, 2023 | 12 |
| NCT05387733Adiposis Dolorosa · United States | 2 | Completed | Apr 3, 2023 | 12 |
| NCT05234736Subcutaneous Fat · United States | 2 | Completed | Jun 9, 2022 | 10 |
| NCT04897412Subcutaneous Fat · United States, Australia | 2 | Completed | Feb 22, 2023 | 75 |
| NCT04699669Subcutaneous Fat · Australia | 1 | Completed | Aug 20, 2019 | 40 |
| NCT04698642Subcutaneous Fat · Australia | 2 | Completed | Nov 12, 2020 | 43 |
| NCT04575467Subcutaneous Fat · Australia | 2 | Completed | Nov 15, 2021 | 25 |
How it is read
Names in the registry
- “CBL-514 Injection”, 7 entries
- “CBL-514”, 4 entries
- “CBL-514 injection”, 3 entries
- “40 mg CBL-514”, 1 entry
- “60 mg CBL-514”, 1 entry
Codes read as this program: CBL514.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.